Hmdb loader
Survey
Record Information
Version5.0
StatusDetected and Quantified
Creation Date2009-11-03 00:25:37 UTC
Update Date2023-05-30 20:55:50 UTC
HMDB IDHMDB0013132
Secondary Accession Numbers
  • HMDB13132
Metabolite Identification
Common NameHydroxyvalerylcarnitine
DescriptionHydroxyvalerylcarnitine is an acylcarnitine. More specifically, it is an hydroxyvaleric acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279 ). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review (PMID: 35710135 ), acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Hydroxyvalerylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine hydroxyvalerylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980 ). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular hydroxyvalerylcarnitine is elevated in the blood or plasma of individuals with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (PMID: 28583327 ) and holocarboxylase synthetase deficiency (PMID: 27114915 ). It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 33391503 ). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643 ). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available (PMID: 35710135 ).
Structure
Data?1614293133
SynonymsNot Available
Chemical FormulaC12H23NO5
Average Molecular Weight261.318
Monoisotopic Molecular Weight261.158
IUPAC NameNot Available
Traditional NameNot Available
CAS Registry NumberNot Available
SMILES
[H]C(O)(CC)CC(=O)O[C@@]([H])(CC([O-])=O)C[N+](C)(C)C
InChI Identifier
InChI=1S/C12H23NO5/c1-5-9(14)6-12(17)18-10(7-11(15)16)8-13(2,3)4/h9-10,14H,5-8H2,1-4H3/t9?,10-/m0/s1
InChI KeySHDVOJJCEZGPBX-AXDSSHIGSA-N
Chemical Taxonomy
ClassificationNot classified
Ontology
Physiological effect
Disposition
Biological locationRoute of exposureSource
Process
Role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility2.28 g/LALOGPS
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+165.62130932474
DeepCCS[M-H]-162.27930932474
DeepCCS[M-2H]-198.01930932474
DeepCCS[M+Na]+174.25430932474
AllCCS[M+H]+164.032859911
AllCCS[M+H-H2O]+161.032859911
AllCCS[M+NH4]+166.732859911
AllCCS[M+Na]+167.532859911
AllCCS[M-H]-168.932859911
AllCCS[M+Na-2H]-169.832859911
AllCCS[M+HCOO]-170.832859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
HydroxyvalerylcarnitineCCC(O)CC(O)O[C@@H](CC([O-])=O)C[N+](C)(C)C2772.8Standard polar33892256
HydroxyvalerylcarnitineCCC(O)CC(O)O[C@@H](CC([O-])=O)C[N+](C)(C)C1565.9Standard non polar33892256
HydroxyvalerylcarnitineCCC(O)CC(O)O[C@@H](CC([O-])=O)C[N+](C)(C)C1849.0Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Hydroxyvalerylcarnitine,1TMS,isomer #1CCC(CC(O)O[C@@H](CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C1839.4Semi standard non polar33892256
Hydroxyvalerylcarnitine,1TMS,isomer #2CCC(O)CC(O[C@@H](CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C1829.5Semi standard non polar33892256
Hydroxyvalerylcarnitine,2TMS,isomer #1CCC(CC(O[C@@H](CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C1848.6Semi standard non polar33892256
Hydroxyvalerylcarnitine,1TBDMS,isomer #1CCC(CC(O)O[C@@H](CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C2062.3Semi standard non polar33892256
Hydroxyvalerylcarnitine,1TBDMS,isomer #2CCC(O)CC(O[C@@H](CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C2039.2Semi standard non polar33892256
Hydroxyvalerylcarnitine,2TBDMS,isomer #1CCC(CC(O[C@@H](CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C2319.4Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Hydroxyvalerylcarnitine GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Hydroxyvalerylcarnitine 10V, Positive-QTOFsplash10-03di-0190000000-912bc2725d99bd01eec32021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Hydroxyvalerylcarnitine 20V, Positive-QTOFsplash10-000i-9400000000-b7546bc84d9c4708d4d22021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Hydroxyvalerylcarnitine 40V, Positive-QTOFsplash10-000i-9000000000-4508114e92c2ad644e0f2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Hydroxyvalerylcarnitine 10V, Negative-QTOFsplash10-0aor-7900000000-34ed98270bb1cd5138e32021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Hydroxyvalerylcarnitine 20V, Negative-QTOFsplash10-0a4i-9300000000-33707be75f6b0f6886fe2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Hydroxyvalerylcarnitine 40V, Negative-QTOFsplash10-0a4l-9100000000-a64e38da3e0f16f6c83a2021-09-24Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
  • Feces
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
BloodDetected and Quantified0.020-0.100 uMAdult (>18 years old)BothNormal details
BloodDetected and Quantified<0.110 uMNot SpecifiedNot SpecifiedNormal details
FecesDetected and Quantified0.38 +/- 0.24 nmol/g wet fecesAdult (>18 years old)Both
Normal
details
FecesDetected and Quantified0.2 +/- 0.09 nmol/g wet fecesAdult (>18 years old)Both
Normal
details
UrineDetected and Quantified143.75 +/- 6.21 umol/mmol creatinineAdolescent (13-18 years old)Both
Normal
details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
UrineDetected and Quantified0.14 (0.10-0.21) umol/mmol creatinineNewborn (0-30 days old)Both
Normal
    • Analysis of 40 NI...
details
UrineDetected and Quantified0.04-0.29 umol/mmol creatinineNewborn (0-30 days old)BothNormal details
UrineDetected and Quantified0.06(0.05-0.13) umol/mmol creatinineNewborn (0-30 days old)FemaleNormal details
UrineDetected and Quantified0.08(0.04-0.33) umol/mmol creatinineNewborn (0-30 days old)MaleNormal details
Abnormal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected and Quantified0.0602 (0.0527) uMAdult (>18 years old)FemalePregnancy with fetus having congenital heart defect details
BloodDetected and Quantified0.024 +/- 0.009 uMChildren (1-13 years old)Both
Obesity
    • Metabolomics reve...
details
BloodDetected and Quantified0.023 +/- 0.007 uMChildren (1-13 years old)Both
Obesity
    • Metabolomics reve...
details
UrineDetected and Quantified193.30 +/- 6.69 umol/mmol creatinineAdolescent (13-18 years old)Both
Obese
details
Associated Disorders and Diseases
Disease References
Obesity
  1. Cho K, Moon JS, Kang JH, Jang HB, Lee HJ, Park SI, Yu KS, Cho JY: Combined untargeted and targeted metabolomic profiling reveals urinary biomarkers for discriminating obese from normal-weight adolescents. Pediatr Obes. 2017 Apr;12(2):93-101. doi: 10.1111/ijpo.12114. Epub 2016 Feb 22. [PubMed:26910390 ]
  2. Simone Wahl, Christina Holzapfel, Zhonghao Yu, Michaela Breier, Ivan Kondofersky, Christiane Fuchs, Paula Singmann, Cornelia Prehn, Jerzy Adamski, Harald Grallert, Thomas Illig, Rui Wang-Sattler, Thomas Reinehr (2013). Metabolomics reveals determinants of weight loss during lifestyle intervention in obese children. Metabolomics.
Associated OMIM IDs
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound145453469
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDMDB00000851
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
  2. Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
  3. Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
  4. Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
  5. Violante S, Ijlst L, Ruiter J, Koster J, van Lenthe H, Duran M, de Almeida IT, Wanders RJ, Houten SM, Ventura FV: Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched-chain amino acid metabolism. Biochim Biophys Acta. 2013 Jun;1832(6):773-9. doi: 10.1016/j.bbadis.2013.02.012. Epub 2013 Feb 24. [PubMed:23485643 ]
  6. Grunert SC, Schlatter SM, Schmitt RN, Gemperle-Britschgi C, Mrazova L, Balci MC, Bischof F, Coker M, Das AM, Demirkol M, de Vries M, Gokcay G, Haberle J, Ucar SK, Lotz-Havla AS, Lucke T, Roland D, Rutsch F, Santer R, Schlune A, Staufner C, Schwab KO, Mitchell GA, Sass JO: 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: Clinical presentation and outcome in a series of 37 patients. Mol Genet Metab. 2017 Jul;121(3):206-215. doi: 10.1016/j.ymgme.2017.05.014. Epub 2017 May 22. [PubMed:28583327 ]
  7. FRITZ IB: Action of carnitine on long chain fatty acid oxidation by liver. Am J Physiol. 1959 Aug;197:297-304. doi: 10.1152/ajplegacy.1959.197.2.297. [PubMed:13825279 ]
  8. Makarova E, Makrecka-Kuka M, Vilks K, Volska K, Sevostjanovs E, Grinberga S, Zarkova-Malkova O, Dambrova M, Liepinsh E: Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific Insulin Sensitivity. Front Endocrinol (Lausanne). 2019 Dec 17;10:870. doi: 10.3389/fendo.2019.00870. eCollection 2019. [PubMed:31920980 ]
  9. Chen C, Hou G, Zeng C, Ren Y, Chen X, Peng C: Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis. Theranostics. 2021 Jan 1;11(2):754-767. doi: 10.7150/thno.51154. eCollection 2021. [PubMed:33391503 ]
  10. Donti TR, Blackburn PR, Atwal PS: Holocarboxylase synthetase deficiency pre and post newborn screening. Mol Genet Metab Rep. 2016 Apr 6;7:40-4. doi: 10.1016/j.ymgmr.2016.03.007. eCollection 2016 Jun. [PubMed:27114915 ]
  11. Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, Smesny S, Sen ZD, Guo AC, Oler E, Tian S, Zheng J, Wishart DS, Liepinsh E, Schioth HB: Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacol Rev. 2022 Jul;74(3):506-551. doi: 10.1124/pharmrev.121.000408. [PubMed:35710135 ]
  12. Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.